The Committee for Human Use (CHMP) of the EMA has at its meeting in February 2011 recommended to extend the indication for adalimumab
adalimumab (Humira) should in future be used for the treatment of juvenile idiopathic arthritis in patients aged between 4 and 12 years.
Source:
Press release of 18 EMA February 2011
0 comments:
Post a Comment